DMAP Supplemental Rebate Agreements

• Supplemental Rebate Agreement (PDF)
• Supplemental Rebate Instructions (PDF)
• Supplemental Rebate Governing Rules (PDF) 
• Supplemental Rebate Letters

_____________________________________________________________________________________________

DMAP posts supplemental rebate letters to this page January 1 and July 1 of each year to announce that it will consider drugs for inclusion on the Plan Drug List. Drug manufacturers then have 60 days from the date of the letter to submit supplemental rebate agreements that offer their drugs for consideration.

• Agreements submitted between July 1 and Aug. 31 will be considered for PDL changes effective Jan. 1 of the following year.
• Agreements submitted between Jan. 1 and Feb. 28 will be considered for PDL changes effective July 1 of the same year.

DMAP will consider supplemental rebate offers that result in cost savings without impacting the quality of prescription drug therapy. When the Health Resources Commission advises that a drug is eligible for the Plan Drug List, drug manufacturers can have their drug listed if the drug's net price is less than or equal to the list's benchmark price. DMAP will evaluate supplemental rebate offers based on net cost to the state.

Supplemental Rebate Letters

Feb. 28, 2007 (PDF): Rebate submission deadline extended to March 30, 2007.

Jan. 22, 2007 (PDF): All drug classes reviewed by the Health Resources Commission to date, for supplemental rebates to be effective July 1.

July 1, 2006 (PDF): All drug classes reviewed by the Health Resources Commission to date, for supplemental rebates to be effective Jan. 1, 2007.

June 15, 2006 (PDF): Antiplatelets and Targeted Immuno Modulators will not be in PDL

April 1, 2006 (PDF): Alzheimers drugs; antiplatelets; proton pump inhibitors (PPIs)

February 1, 2006 (PDF): Nonsteroidal anti-inflammatory drugs (NSAIDs); long-acting opioids; thiazolidinediones

December 20, 2005 (PDF): Angiotensin-converting enzyme inhibitors, Angiotensin II receptor blockers, statins, inhaled corticosteroids, newer antiemetics, non-sedating antihistamines

September 30, 2005 (PDF): Triptans, newer sedatives, overactive bladder drugs, targeted immune modulators

May 13, 2005 (PDF): Calcium channel blockers, Alzheimer drugs, long-acting opioids, anti-platelet drugs, beta-blockers, skeletal muscle relaxants, overactive bladder drugs, proton pump inhibitors, oral hypoglycemics

December 15, 2004 (PDF): Inhaled corticosteroids

Back to top